Trials / Completed
CompletedNCT00082316
Tolerability of Three Local Anesthetic Formulations in Conjunction With NGX-4010 for the Treatment of Neuropathic Pain
A Randomized, Open-Label Study of the Tolerability of Three Local Anesthetic Formulations in Conjunction With NGX-4010 for the Treatment of Neuropathic Pain
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- NeurogesX · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a randomized, open-label multi-center evaluation of the tolerability of treatment with NGX-4010 in conjunction with pre-patch topical application of one of three 4% lidocaine-based local anesthetic products. Eligible subjects will have moderate to severe neuropathic pain secondary to painful diabetic neuropathy (PDN), postherpetic neuralgia (PHN) or HIV-associated neuropathy (HIV-AN), with average numeric pain rating scale (NPRS) scores during screening of 3 to 8 (inclusive).
Conditions
- Herpes Zoster
- Neuralgia
- Pain
- HIV Infections
- Peripheral Nervous System Diseases
- Diabetic Neuropathies
- Diabetes Mellitus
- Polyneuropathies
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Capsaicin Dermal Patch |
Timeline
- First posted
- 2004-05-07
- Last updated
- 2008-01-11
Locations
17 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00082316. Inclusion in this directory is not an endorsement.